Salarius Pharmaceuticals changed its corporate name to Decoy Therapeutics and shifted its public-company identity to preclinical peptide-conjugate therapeutics. Company news centers on Decoy's machine-learning and AI-enabled platform for designing, engineering and manufacturing peptide conjugate drug candidates, with an initial pipeline focused on respiratory viruses and gastrointestinal cancers.
Recurring updates also cover shareholder votes, governance matters, capital-structure actions, Nasdaq listing compliance, and clinical or regulatory disclosures tied to its biotechnology programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.